News

Yesterday, GHTC delivered an intervention during the first round of public hearings on the development of a potential pandemic treaty, which emphasized that the research and development of health technologies, coupled with sustainable financing for research capacity strengthening, should be a central pillar of any framework.In December 2021, the World Health Assembly established an intergovernmental negotiating body to draft and negotiate a World Health Organization (WHO) convention, agreement, or other international instrument on pandemic prevention, preparedness, and response.The guiding question of the first round of public hearings was: What substantive elements do you think should be included in a new international instrument on pandemic preparedness and response?GHTC's intervention as prepared is below and also available via video on the WHO website: The Global Health Technologies Coalition welcomes the opportunity to provide input to the Intergovernmental Negotiating Body (INB) through these public hearings. As deliberations around the creation of this framework continue, we urge member states to consider the following essential elements:Firstly, while these consultations represent a good first step, civil society must continue to be involved in the creation of the instrument itself, including the drafting process. Furthermore, members of the INB should ensure that a broad spectrum of voices can be heard during these discussions, especially those from lower- and middle-income (LMIC) countries and experts.  Second, research and development must be a central pillar of the framework. This includes strengthening norms and standards that support access and benefit sharing of data related to emerging pathogens, supporting mechanisms that strengthen local manufacturing and regulatory capacity, and facilitating research coordination that spurs innovation and the development of novel medical countermeasures that are accessible to all who need them.Lastly, the new instrument should be coupled with sustainable financing mechanisms, including a new global pandemic preparedness fund that increases surveillance, clinical trial, manufacturing capacities, as well as health system infrastructure strengthening in LMIC countries to address both pandemic and existing health priorities.  

Interested in more global health innovation news? Every week GHTC scours media reports worldwide to deliver essential global health R&D news and content to your inbox. Sign up now to receive our weekly R&D News Roundup email. Last week, advisers to the US Food and Drug Administration convened to assess the country’s COVID-19 vaccine policy, including guidance on updated vaccines to offer increased protection against variants. Some health officials believe revised vaccines will be needed by the fall, when the virus could resurge in force. Researchers developing modified vaccines would need to settle on a formula as early as June to have a vaccine ready for use this fall, according to the panel, though several trials are just now getting underway—including a National Institutes of Health study analyzing a Moderna vaccine revised to target three different variants, for which results are expected this summer. Once regulators decide on a reconfigured vaccine, manufacturers would need several months to produce doses, according to one expert, and several others underscored the uncertainty and difficulty of the highly compressed timeline.Moderna and IAVI will collaborate to develop vaccines and antibodies for HIV/AIDS, tuberculosis, antimicrobial-resistant enteric infections, and COVID-19 using mRNA technology, the organizations announced Thursday. The partnership aims to accelerate the research and development process, as Moderna’s mRNA platform can help develop material for clinical testing more quickly than traditional recombinant protein synthesis or cell systems can. If candidates are successful, they can also be manufactured quickly and at large scale, according to Moderna. The first candidate the partnership will work on is HIV vaccine antigens delivered by mRNA, for which a phase 1 trial was initiated in January. Preclinical efforts in the collaboration include candidates for tuberculosis, COVID-19, and HIV.The world needs to invest $15 billion this year, and $10 billion annually in future years, to establish and maintain an adequate toolkit to respond to COVID-19 and future pandemic threats, according to a working paper released by the International Monetary Fund last week. The paper, published in partnership with the Coalition for Epidemic Preparedness Innovations, the Global Fund, and Wellcome Trust, outlines the funding estimate while asserting that ending the pandemic everywhere remains an urgent economic, health, and moral priority for the world. Countries need vaccines, tests, treatments, and an improved health infrastructure to tackle COVID-19 and other deadly diseases, as well as investments in global surveillance, research and development, manufacturing, and health systems, global leaders said.

Interested in more global health innovation news? Every week GHTC scours media reports worldwide to deliver essential global health R&D news and content to your inbox. Sign up now to receive our weekly R&D News Roundup email.On Thursday, the World Health Organization launched a new global initiative to combat arboviruses—fast-growing and poorly understood viral diseases carried by insects that have future pandemic potential. The Global Arbovirus Initiative aims to tackle diseases like dengue, yellow fever, chikungunya, and Zika, which currently have limited effective treatments and vaccines. The initiative will better link the various research, surveillance, and vector control efforts around the world in a more formal network of collaboration. Research innovation and partnerships are also key to the new strategy, which is the culmination of a series of consultations among a broad network of partners to enable efficient and successful collaboration across a range of pathogens and disciplines and ensure a more integrated approach to this family of viruses.The US Food and Drug Administration on Tuesday approved HIV treatment Cabenuva for adolescents, the first long-acting injectable regimen for the age group. The treatment, which includes shots of cabotegravir and rilpivirine, was approved for adults last year as a monthly regimen and more recently as a bimonthly regimen, meaning it can be administered as few as six times per year. Both timing options will now be available to virologically suppressed adolescents aged 12 years or older who weigh at least 35 kg, are on a stable antiretroviral therapy regimen, and have no history of treatment failure or resistance to either drug. The approval for adolescents is supported by evidence from studies conducted among adults as well as from interim analysis of an ongoing trial among adolescents.Ahead of a World Health Assembly (WHA) meeting in May, the United Kingdom is circulating a resolution to improve the quality of clinical trials by boosting funding, adding more trial sites, and fully reporting study results. The proposal, which comes amid increased concerns about meeting global health needs in the wake of COVID-19, promotes steps to generate “high-quality research” that can help develop medical products to provide routine care, especially in lower- and middle-income countries, for any global health priority. These steps include coordinating research, ensuring funding, and creating mechanisms to register trials and report results. If the resolution proceeds after member state debate, revisions are expected between now and the WHA session in early May.